1 April 2016 - The fixed-dose combination of sacubitril and valsartan (Entresto) has been approved in Europe since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German IQWiG has examined in an early benefit assessment whether this new combination product offers an additional clinical benefit for patients in comparison with the appropriate comparator therapy.

According to the findings, the positive effects regarding mortality, necessity of heart failure hospitalizations, and quality of life predominate. These were not put into question by a negative effect in non-severe side effects; hence overall an indication of considerable additional benefit can be derived from the data.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/sacubitril/valsartan-in-chronic-heart-failure-indication-of-considerable-added-benefit.7235.html

To see this entry for Entresto in the MAESTrO database, go to: https://app.maestrodatabase.com/app/reimbursement/browse/technology/sacubitril-with-valsartan?agency=iqwig